GlamCO KLOW Blend
99%+ Purity
Verified by HPLC
Home / Catalog / KLOW Blend

KLOW Blend

$140.00
Made in USA
cGMP Compliant

KLOW is a four-peptide research blend co-lyophilized for in vitro investigation of converging tissue-repair, inflammation, and extracellular-matrix pathways. Composition: KPV + BPC-157 + GHK-Cu + TB-500 - allowing study of NF-kappaB, VEGF, copper-ECM, and actin-thymosin pathways in a single experimental matrix.

Tier Quantity Discount
Most Popular 3 - 5 10%
Max Savings 6 + 15%
Secure Checkout | Third-Party Tested | Free Shipping $100+
Sterility & Endotoxins PASSED
Net Content & Purity PASSED
Third-Party Lab Verified

Independently Tested. Verifiably Pure.

Every batch of KLOW Blend is sent to an accredited independent laboratory before it ships. Each of the four constituent peptides - KPV, BPC-157, GHK-Cu, and TB-500 - is verified for identity, purity, and net content prior to co-lyophilization. Here is exactly what we screen for, and the certificate that proves it.

What We Test Every Batch For

HPLC Purity Analysis
Confirms the peptide is ≥99% pure
Mass Spectrometry
Verifies the exact molecular identity
Heavy Metals Screening
Lead, arsenic, cadmium & mercury - Pass
Endotoxins (LPS)
Bacterial endotoxin levels - Pass
Sterility Testing
No microbial contamination - Pass
TFA Content
Residual trifluoroacetic acid - Not Detected
Net Peptide Content
Actual peptide mass per vial verified
📄
50+
Published Studies
GHRH analog research papers
🧬
44
Amino Acids
Full-length GHRH(1-44) analog
2010
FDA Approval (Egrifta)
HIV-associated lipodystrophy
🛡️
99%+
Purity Verified
HPLC tested, COA included
Research Mechanism

How KLOW Blend Works

Four mechanistically distinct peptides studied for converging effects on inflammation, angiogenesis, extracellular matrix, and cytoskeletal dynamics

K - KPV

NF-kappaB Suppression

KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-MSH, has been reported in vitro to block the importin-alpha/p65 NF-kappaB nuclear translocation pathway, suppressing pro-inflammatory cytokine transcription independently of melanocortin receptors.

  • Inhibits NF-kappaB nuclear import
  • Reduces TNF-alpha and IL-1beta signaling in models
  • Studied in colitis and dermatitis research models
L - BPC-157

VEGF & Nitric Oxide Pathways

BPC-157, a 15-amino-acid fragment derived from gastric Body Protection Compound, is reported in preclinical models to upregulate VEGFR2, modulate the nitric oxide system, and influence angiogenic and gut-barrier signaling.

  • Upregulates VEGFR2-driven angiogenesis in vitro
  • Modulates eNOS and NO-system signaling
  • Studied in tendon, ligament, and gut-barrier models
O - GHK-Cu

Copper-Tripeptide ECM Signaling

GHK-Cu (Gly-His-Lys-Cu2+) is a copper-binding tripeptide reported to modulate gene expression related to collagen synthesis, decorin, antioxidant defense, and extracellular matrix remodeling in dermal fibroblast cultures.

  • Modulates collagen and decorin gene expression
  • Studied in fibroblast and skin-equivalent models
  • Reported antioxidant and matrix-remodeling activity
Reported Findings

What Research Has Shown

Selected preclinical findings across the four constituent peptides

KPV - NF-kappaB Suppression (Cell Models) ~70%
BPC-157 - Tendon Fibroblast Outgrowth (Rodent) Reported ↑
GHK-Cu - Collagen Gene Expression (Fibroblasts) ~70%
TB-500 - G-Actin Sequestration Activity Established
Investigational Fields

Research Applications

Primary domains of KLOW-component investigation

Gut Barrier

Gut Barrier Research

KPV and BPC-157 are both studied in intestinal-epithelial models for effects on tight-junction integrity, mucosal inflammation, and DSS-colitis paradigms - making KLOW a candidate matrix for studying combinatorial gut-barrier modulation in vitro.

Dalmasso et al. 2008 ↗
Tight Junctions

Tight-Junction Research

BPC-157 and KPV literature describes effects on zonulin, occludin, and claudin expression in intestinal and epithelial barrier models, used to probe permeability changes under inflammatory challenge.

Sikiric et al. 2018 ↗
Anti-Inflammatory

Anti-Inflammatory Pathway Research

All four KLOW components have been studied for effects on NF-kappaB, cytokine release, and oxidative-stress markers, supporting investigation of multi-target inflammation pharmacology in cell and tissue models.

Pickart & Margolina 2017 ↗
Combinatorial

Combinatorial Peptide Pharmacology

KLOW serves as a research scaffold for studying additive or synergistic effects between distinct peptide pharmacologies (NF-kappaB, VEGF, copper-ECM, actin-thymosin) without requiring four separate reconstitutions.

Goldstein et al. 2005 ↗
Technical Specifications

Compound Information

Per-component sequence, mass, and analytical profile

Blend Composition
KPV + BPC-157 + GHK-Cu + TB-500 (co-lyophilized)
K - KPV Sequence
Lys-Pro-Val (3 aa); ~341.4 Da; alpha-MSH(11-13) fragment
L - BPC-157 Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 aa); ~1419.5 Da
O - GHK-Cu Structure
Gly-His-Lys + Cu2+ coordination complex; ~340.8 Da basic peptide + Cu
W - TB-500 Sequence
Active region of Thymosin Beta-4 (17 aa fragment); ~888 Da
Standard Total Mass
80 mg per vial (industry-standard KLOW configuration)
Form
Co-lyophilized powder
Purity
≥99% (HPLC verified prior to blending)
Testing
Third-party HPLC, Mass Spec, Endotoxin
Storage (lyophilized)
-20°C for long-term stability
Storage (reconstituted)
2-8°C, use within 14 days
Solubility
Bacteriostatic water for reconstitution
COA
Included with every order
Common Inquiries

Frequently Asked Questions

Common questions about the KLOW Blend research matrix

Transparency note on composition: "KLOW" is a research-blend name used across the peptide-research industry, but the letter mapping is not formalized by any standards body. After surveying multiple supplier descriptions, the most widely used interpretation - and the one we adopt here - is K = KPV, L = BPC-157 (a Lys-stabilized fragment derived from gastric BPC), O = GHK-Cu, W = TB-500. The total standard mass is typically 80 mg per vial. Our COA discloses the exact per-component mass for every batch so researchers can verify the composition directly rather than relying on the name.
No. KLOW Blend is not an approved drug product and is not intended for human or veterinary use. It is supplied as a research-grade reagent for in vitro investigation only. None of the four constituent peptides hold FDA approval as a finished pharmaceutical in this combination.
Each peptide in KLOW maps to a distinct mechanistic axis (NF-kappaB, VEGF/NO, copper-ECM, actin-thymosin). Researchers studying convergent inflammation-repair pathways often need to expose cell or tissue models to all four simultaneously. A co-lyophilized blend reduces pipetting variance, single-component degradation differences, and reconstitution-step contamination risk in multi-peptide experiments.
Each individual peptide is HPLC- and mass spec-tested to ≥99% purity before blending. Post-blend, the lyophilized matrix is re-screened by HPLC to confirm that all four peaks are present at the expected relative ratios. The COA documents both single-component and post-blend results.
KLOW is intended as a fixed-ratio combinatorial reagent, not as a source of isolated single components. Researchers needing per-peptide dose-response curves should source KPV, BPC-157, GHK-Cu, and TB-500 individually. KLOW is most useful when the experimental question concerns the combined matrix rather than any one constituent.
Lyophilized KLOW should be stored at -20°C for long-term stability. Reconstitution is typically performed with bacteriostatic water; once reconstituted, store at 2-8°C and used within 14 days. Avoid repeated freeze-thaw cycles and protect from light. The copper-binding GHK component is sensitive to strongly reducing or chelating buffers.
Academic Literature

Sources & References

Peer-reviewed publications and clinical studies database

PUBMED

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

2008 · Dalmasso G et al. · Gastroenterology
View Source ↗
PUBMED

Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease

2018 · Sikiric P et al. · Curr Pharm Des
View Source ↗
PUBMED

The Effect of the Human Peptide GHK on Gene Expression and Skin Regeneration

2017 · Pickart L, Margolina A · Brain Sci
View Source ↗
PUBMED

Thymosin beta 4: actin-sequestering protein moonlights to repair injured tissues

2005 · Goldstein AL et al. · Trends Mol Med
View Source ↗